Sterility Assurance & Annex 1 Consulting Biopharma

Q: What does GMP Bridge typically support under sterility assurance and Annex 1 compliance?

We support biopharma manufacturers with Contamination Control Strategy (CCS) development or remediation, Contamination Control Risk Assessments (CCRA), Environmental Monitoring optimization, aseptic behavior oversight, gowning qualification, material transfer controls, and practical Annex 1 gap remediation.

Q: Can GMP Bridge help us build or improve our Contamination Control Strategy (CCS)?

Yes. We help companies design or strengthen a CCS that is risk-based, operationally usable, and aligned with Annex 1 expectations. Our approach focuses on translating regulatory requirements into practical controls that work in daily manufacturing, not just on paper.

Q: Do you only assess gaps, or do you also support implementation?

We do both. GMP Bridge supports clients from gap assessment and risk review through to hands-on implementation, including program redesign, procedural improvements, training, Quality Oversight, and execution support on the shop floor.

Q: Is this service relevant only after a regulatory finding or contamination event?

No. We support both proactive and remediation-driven projects. Companies often engage us before inspections, during Annex 1 readiness work, after recurring sterility assurance concerns, or when they need to strengthen contamination control before issues escalate into batch impact or regulatory exposure.

Q: What makes GMP Bridge different in sterility assurance projects?

Every project is led by senior consultants with hands-on aseptic manufacturing experience. GMP Bridge’s focus is on structured, risk-based, and inspection-ready sterility assurance that improves real operational control, not just documentation.

Sterility Assurance and Annex 1 Compliance Consulting for Biopharma

Contamination risks often arise from inconsistent control and execution

Gaps in Sterility Assurance

Sterility assurance requires consistent control across processes, environments, and human behavior. In practice, many organizations face gaps in contamination control, unclear responsibilities and inconsistent application of aseptic standards.

With increasing regulatory expectations, including EU GMP Annex 1, weaknesses in sterility assurance quickly lead to compliance risks, deviations, and inspection findings.

Strengthening contamination control and sterility assurance

Risk-Based Sterility Assurance

We help biopharma organizations strengthen sterility assurance through practical, risk-based measures aligned with Annex 1 expectations. The focus is on building robust contamination control, improving operational discipline, and translating regulatory requirements into sustainable actions that work in the real manufacturing environment.

What we offer

Key Elements of Sterility Assurance

Contamination Control Strategy (CCS)

Development and implementation of integrated CCS aligned with Annex 1.

Contamination Control Risk Assessment (CCRA)

Risk-based identification and evaluation of contamination sources and controls.

Aseptic Process & Environment Control

Strengthening environmental monitoring, material flow, and intervention control.

Behavior & Practices

Improving gowning, aseptic techniques and operator behavior in critical areas.

Reduced contamination risk and robust sterility assurance

What You Achieve

GMP Bridge strengthens sterility assurance by aligning contamination control strategies, operational practices, and regulatory expectations ensuring sustainable control across all critical areas.

Reduced Contamination Risk

Stronger control of critical risks across processes, environments, and people.

Annex 1 Compliance

Structured implementation of contamination control strategies aligned with regulatory expectations.

Consistent Aseptic Practices

Improved execution and discipline in critical manufacturing areas.

Sustainable Control

Long-term stability of sterility assurance systems and processes.

Strengthen Your Sterility AssuranceLet's talk!

Schedule your call

FAQs

Frequently Asked Questiions

What does GMP Bridge typically support under sterility assurance and Annex 1 compliance?

Can GMP Bridge help us build or improve our Contamination Control Strategy (CCS)?

Do you only assess gaps, or do you also support implementation?

Is this service relevant only after a regulatory finding or contamination event?

What makes GMP Bridge different in sterility assurance projects?